IL6 and schizophrenia: In an 8-week open label clinical trial with the concomitant administration of i.v. tocilizumab (an IL-6 inhibitor) every 4 weeks along with the non-clozapine antipsychotic drugs, there was a significant improvement in BACS (brief assessment of cognition in schizophrenia), and verbal fluency after 4 weeks, compared to baseline levels.